Aadi Bioscience Q3 EPS $(0.60) Vs $(0.68) Prior Year, Sales $5.96M Miss $6.61M Estimate
Portfolio Pulse from Benzinga Newsdesk
Aadi Bioscience reported Q3 losses of $(0.60) per share, an 11.76% improvement from $(0.68) per share last year. However, the company's quarterly sales of $5.96 million missed the analyst consensus estimate of $6.61 million by 9.85%, despite a 40.38% increase from $4.25 million the same period last year.
November 08, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Aadi Bioscience's Q3 earnings show an improvement in EPS but a miss in sales estimates. This mixed result could lead to uncertainty in the market.
Aadi Bioscience's Q3 earnings report shows a positive trend in EPS, indicating improved profitability. However, the company missed sales estimates, which could be a concern for investors. The mixed results may lead to uncertainty in the market, potentially affecting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100